Vivos Therapeutics Plans Rights Offering for Capital Raise

Vivos Therapeutics, Inc. announced its intention to file a registration statement with the SEC for a proposed rights offering. This offering aims to distribute transferable subscription rights to shareholders as a dividend, providing the company with additional capital for operations and general corporate purposes. Preliminary terms include an exercise price of the greater of $1.25 per share or 20% above market, a 9-month exercise period, and a subsequent 'exploding' right. The offering is subject to SEC effectiveness, shareholder approval, and other conditions, with no assurance of completion.